SCHEMBL7914627

SCHEMBL7914627

CC(C)(C)[N+]([O-])=CC=Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
MAOB P27338 1/20 0.48
FBP1 P09467 1/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPK1 P28482 2/20 0.42
TRPA1 O75762 1/20 0.42
LMNA P02545 1/20 0.42
ALOX5 P09917 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
CHAT P28329 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HTT P42858 1/20 0.38
NFE2L2 Q16236 1/20 0.37
CYP2C19 P33261 1/20 0.37
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL244830 0.75 TDP1 (0.59) FBP1ALDH1A1TDP1KMT2APOLB
SCHEMBL267779 0.75 TDP1 (0.59) FBP1ALDH1A1TDP1KMT2APOLB
SCHEMBL6260317 0.75 TDP1 (0.59) FBP1ALDH1A1TDP1KMT2APOLB
SCHEMBL9631441 0.74 HTR2A (0.41) NPC1RAB9AMAOBFBP1TDP1
Hydrogen Sulfide SCHEMBL28326251 0.74 TDP1 (0.58) FBP1ALDH1A1TDP1KMT2APOLB
SCHEMBL14477633 0.73 NPC1 (0.56) NPC1RAB9AMAOBFBP1ALDH1A1
SCHEMBL4314330 0.73 NPC1 (0.56) NPC1RAB9AMAOBFBP1ALDH1A1
SCHEMBL13164321 0.72 NPC1 (1.00) NPC1RAB9AMAOBFBP1ALDH1A1
SCHEMBL2998732 0.72 NPC1 (1.00) NPC1RAB9AMAOBFBP1ALDH1A1
SCHEMBL2069217 0.72 NPC1 (1.00) NPC1RAB9AMAOBFBP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6194461-B1 USEFUL AS MEDICAMENT FOR TREATING RETINAL DEGENERATIVE DISORDERS; ALPHA-(2,4-DIFLUOROPHENYL)-N-T-BUTYLNITRONE, AND CORRESPONDING AMINES WHICH WOULD BE CONVERTED IN VIVO TO THE NITRONE, FOR EXAMPLE SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-02-27 US disclosed
EP-0945426-A1 NITRONE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1999-09-29 EP disclosed